Baird Maintains Bullish View on Intercept Pharmaceuticals (ICPT), Concerns Overblown
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Intercept Pharmaceuticals Reports Third Quarter 2016 Financial Results and Provides Business Update
November 3, 2016 7:05 AM EDTNet Ocaliva® (obeticholic acid or OCA) 3Q sales of $4.7 million Positive opinion adopted by Committee of Medicinal Products in Human Use (CHMP) for Ocaliva in Primary Biliary Cholangitis (PBC) in EUEnrollment in Phase 2 CONTROL trial complete in Nonalcoholic Steatohepatitis (NASH) patients with fibrosisEnrollment in Phase 2 AESOP trial complete in primary sclerosing cholangitis (PSC)
Conference call scheduled for 8:30 a.m. ET today
NEW YORK, Nov. 03, 2016 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc.... More
